medigraphic.com
ISSN 0188-2198 (Impreso)

2007, Número 3

Siguiente >>

Rev Mex Cardiol 2007; 18 (3)


Resultados inmediatos y a largo plazo de angioplastia con stent farmacólogico (paclitaxel) y no farmacológico: Un estudio prospectivo, comparativo en el IMSS Villahermosa

Torres-Hernández ME, Yánez-Rivera TG, Ross-Mayo J, García-Magaña A, De la Cruz-Zurita H, Priego-Brindis JT, Hernández-Márquez S, Ávila-Lucena C, Mejía N

Idioma: Español
Referencias bibliográficas: 28
Paginas: 95-102
Archivo PDF: 117.81 Kb.


RESUMEN

Objetivos: Analizar resultados clínicos a largo plazo en pacientes (pts) llevados a angioplastia coronaria transluminal percutánea (ACTP) con stent farmacológico (GI) y no farmacológico (GII). Material y métodos: De enero 2004 a agosto 2006 se realizaron en 85 pts ACTP. Se analizaron características demográficas, angiográficas y eventos a 6 meses. Punto final primario: Eventos cardiacos adversos mayores (MACE) a 6 meses. Punto final secundario: Necesidad de revascularización de la lesión tratada en diabéticos a 6 meses (TLR-D). Se utilizó test exacto de Fisher y test de U Mann-Whitney. Resultados: Fueron 129 vasos tratados con 76 stent farmacológicos (GI) y 75 no farmacológicos (GII). Hubo más pts en el GI con diabetes (72% vs 45%, p = 0.004), hipertensión (83% vs 67%, p = 0.051), vasos enfermos (1.95 ± 0.9 vs 1.33 ± 0.55, p = 0.001), lesiones más largas (21.9 ± 6.6 vs 18.64 ± 6.4 mm, p = 0.0001) y diámetro de referencia menor (3.05 ± 0.28 vs 3.39 ± 0.48 mm, p = 0.023). Cinco por ciento fue ACTP a tronco no protegido. Puntos finales: MACE a 6 meses GI 1.4% vs GII 11.3%, p = 0.04, IC 95%. TLR-D GI 0% vs GII 9.4%, p = 0.018%. Conclusiones: Los stent farmacológicos se asocian con baja tasa de eventos clínicos adversos a 6 meses, aun en pacientes diabéticos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gruentzig AR, Senning A, Siegenthaler WE. Non-operative dilatation of coronary artery stenosis percutaneous transluminal coronary angioplasty. N Engl J Medicine 1979; 301: 61-68.

  2. Kastrati A, Dirschinger J, Boeckstegers P et al. Influence of stent design of one year outcome after coronary stent placement: a randomized comparison of 5 stent types in 1,147 unselected patients. Catheter Cardiovasc Interv 2000; 50: 290-297.

  3. Kastrati EA, Neumann SJ et al. Vessel size and long term outcome after coronary stent placement. Circulation 1998; 98: 1875-1880.

  4. Hofmann R, Mintz GS. Coronary in stent restenosis-predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-1749.

  5. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successfully balloon angioplasty. Circulation 1994; 90: 1239-1251.

  6. Nobuyoschi M, Kimura T, Nosaka H et al. Restenosis after percutaneous transluminal coronary angioplasty. Serial angioplasty follow up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623.

  7. Kasaoka S, Tobis J, Akuyama T et al. Angiographic and intravascular predictors of restenosis. J Am Coll Cardiol 1998; 32: 1630-1635.

  8. West N, Ruygrok P, Webster M et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 24: 867-873.

  9. Mercado N, Boersna E, Wyns E et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis. J Am Coll Cardiol 2001; 38: 645-652.

  10. Orminston J, Webster M, Ruygrak P et al. Six month angiographic and twelve month clinical follow up of multilink long (25-35 mm) stents for long coronary narrowings in patient with angor pectoris. Am J Cardiol 2002; 90: 222-226.

  11. Morice MC, Serruys P, Sousa J et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 773-780.

  12. Park S, Shim W, Ho D et al. A paclitaxel eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-1545.

  13. Kastratri A, Shpend E, Dirschinger J et al. Influence of lesion length on restenosis after coronary placement. Am J Cardiol 1999; 83: 1617-1622.

  14. Kobayashi Y, De Gregorio J, Kobayashi N et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34: 651-659.

  15. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109: 1244-1249.

  16. Holmes DR, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640.

  17. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients con stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.

  18. Fajadet J, Morice MC, Bode C et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005; 111: 1040-1044.

  19. Grube E, Silber S, Hauptmann KE et al. TAXUS I: six-and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.

  20. Stone GW, Ellis SG, Cox DA et al. A polimer-based, paclitaxel-eluting stent in patient with coronary artery disease. N Engl J Med 2004; 350: 221-231.

  21. Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent : the TAXUS-IV trial. Circulation 2004; 109: 1942-1947.

  22. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents alter discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.

  23. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautions? Circulation 2004; 109: 701-705.

  24. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106: 2649-2651.

  25. Serruys PW, Andrew T, Piek J et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent. The SPIRIT first trial. Eurointervention 2005; 1: 58-65.

  26. Smith SX, Dove JT, Jacobs AK et al. ACC/AHA Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College Cardiology/American Heart Association task force on practice guidelines endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.

  27. Palmerini T, Marzocchi A, Marozzini C et al. Preprocedural levels oif C-Reactive Protein and Leukocyte Counts Predict 9-Month mortality After Coronary Angioplasty for the treatment of Unprotected Left Main Coronary Artery. Eurointervention 2005; 1: 76.

  28. Windecker S, Remondino A, Eberli F, Juni P, Raber L, Togni M et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization (SIRTAX). N Engl J Med 2005; 353: 653-662.




2020     |     www.medigraphic.com